191 related articles for article (PubMed ID: 36825574)
21. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
Nakatani F; Tanaka K; Sakimura R; Matsumoto Y; Matsunobu T; Li X; Hanada M; Okada T; Iwamoto Y
J Biol Chem; 2003 Apr; 278(17):15105-15. PubMed ID: 12560328
[TBL] [Abstract][Full Text] [Related]
22. Promiscuous partnerships in Ewing's sarcoma.
Sankar S; Lessnick SL
Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
Erkizan HV; Uversky VN; Toretsky JA
Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696
[TBL] [Abstract][Full Text] [Related]
24. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
[TBL] [Abstract][Full Text] [Related]
25. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Brenner JC; Feng FY; Han S; Patel S; Goyal SV; Bou-Maroun LM; Liu M; Lonigro R; Prensner JR; Tomlins SA; Chinnaiyan AM
Cancer Res; 2012 Apr; 72(7):1608-13. PubMed ID: 22287547
[TBL] [Abstract][Full Text] [Related]
26. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
28. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
29. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
[TBL] [Abstract][Full Text] [Related]
30. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
Owen LA; Kowalewski AA; Lessnick SL
PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
[TBL] [Abstract][Full Text] [Related]
31. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
[TBL] [Abstract][Full Text] [Related]
32. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
33. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
34. AT-hook DNA-binding motif-containing protein one knockdown downregulates EWS-FLI1 transcriptional activity in Ewing's sarcoma cells.
Kitagawa T; Kobayashi D; Baron B; Okita H; Miyamoto T; Takai R; Paudel D; Ohta T; Asaoka Y; Tokunaga M; Nakagawa K; Furutani-Seiki M; Araki N; Kuramitsu Y; Kobayashi M
PLoS One; 2022; 17(10):e0269077. PubMed ID: 36194562
[TBL] [Abstract][Full Text] [Related]
35. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.
Smith R; Owen LA; Trem DJ; Wong JS; Whangbo JS; Golub TR; Lessnick SL
Cancer Cell; 2006 May; 9(5):405-16. PubMed ID: 16697960
[TBL] [Abstract][Full Text] [Related]
36. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
37. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
39. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.
Hu HM; Zielinska-Kwiatkowska A; Munro K; Wilcox J; Wu DY; Yang L; Chansky HA
J Orthop Res; 2008 Jun; 26(6):886-93. PubMed ID: 18271016
[TBL] [Abstract][Full Text] [Related]
40. Specific and sensitive detection of the EWS/FLI1 fusion protein in Ewing's sarcoma by Western blotting.
Wang M; Nilsson G; Carlberg M; Dricu A; Wejde J; Kreicbergs A; Larsson O
Virchows Arch; 1998 Feb; 432(2):131-4. PubMed ID: 9504857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]